ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

BACKGROUND:We sought to assess the relative effects of individual anaplastic lymphoma kinase (ALK) inhibitors for the treatment of non-small cell lung cancer (NSCLC). METHODS:We searched MEDLINE, Embase, Cochrane CENTRAL, and grey literature (July 23, 2019) for randomized controlled trials (RCTs) th...

Full description

Bibliographic Details
Main Authors:	Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0229179

Similar Items

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
by: Cheng-Hao Chuang, et al.
Published: (2021-04-01)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
by: Deng L, et al.
Published: (2018-09-01)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
by: Mi Ran Yun, et al.
Published: (2019-12-01)

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
by: Dafu Yang, et al.
Published: (2021-02-01)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
by: Hideko Isozaki, et al.
Published: (2015-04-01)

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making.
by: Amy Johnston, et al.
Published: (2018-01-01)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
by: Becky Skidmore, et al.
Published: (2019-06-01)

Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
by: Jesse Elliott, et al.
Published: (2020-01-01)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
by: Barrows SM, et al.
Published: (2019-02-01)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
by: Muhammad Khan, et al.
Published: (2019-01-01)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
by: Iwama E, et al.
Published: (2014-03-01)

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
by: Amanda J.W. Gibson, BSc (Hons), et al.
Published: (2021-04-01)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
by: David M. Waterhouse, et al.
Published: (2020-07-01)

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors
by: Elena Poddubskaya, et al.
Published: (2019-10-01)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
by: Marianne Oulhen, et al.
Published: (2021-07-01)

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
by: Chia PL, et al.
Published: (2014-11-01)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
by: Valerio Gristina, et al.
Published: (2020-12-01)

Second- and third-generation ALK inhibitors for non-small cell lung cancer
by: Jingjing Wu, et al.
Published: (2016-03-01)

ALK inhibitors, a pharmaceutical perspective
by: Arturo eGalvani, et al.
Published: (2012-02-01)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
by: Hou H, et al.
Published: (2019-05-01)

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
by: Kashima J, et al.
Published: (2016-10-01)

Mechanisms of Resistance to EML4-ALK Inhibitors in Non-small Cell Lung Cancer
by: Di WU, et al.
Published: (2013-01-01)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01)

ALK inhibitors fuel ALK resistance mutation: Precision medicine takes on drug resistance
by: Gouri S Bhattacharyya, et al.
Published: (2020-01-01)

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report
by: Chunlai Feng, et al.
Published: (2021-08-01)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor
by: Xinru Chen, et al.
Published: (2017-04-01)

Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK)
by: Fernando Franco, et al.
Published: (2017-03-01)

A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors  and Chemotherapy
by: Jue WANG, et al.
Published: (2021-05-01)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
by: Naoki Haratake, et al.
Published: (2019-09-01)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
by: J. Guan, et al.
Published: (2016-09-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
by: Muhammad Wasi Alam, et al.
Published: (2019-07-01)

ALK‐rearranged squamous cell carcinoma of the lung
by: Qiyi Meng, et al.
Published: (2021-04-01)

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
by: Ken Takahashi, et al.
Published: (2020-03-01)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
by: Satoh H, et al.
Published: (2021-04-01)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
by: Berghmans T, et al.
Published: (2012-12-01)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
by: Pacenta HL, et al.
Published: (2018-10-01)

Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report
by: Wang R, et al.
Published: (2020-05-01)

ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing
by: YC Kheng, et al.
Published: (2018-03-01)

Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer
by: Elisabeth Smolle, et al.
Published: (2021-02-01)